Drug-induced photosensitivity

Hospital Pharmacy

Volumn 41, Issue 2, 2006, Pages 196-206

  Dufner, Kimberly S ^a   Buss, Lori A ^a   Kizito, Joseph ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACICLOVIR; ADAPALENE; ALENDRONIC ACID; ALITRETINOIN; ALMOTRIPTAN; ALPHAN3 INTERFERON; AMFEBUTAMONE; AMINOLEVULINIC ACID; AMIODARONE; AMITRIPTYLINE; ANAGRELIDE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTIPSORIASIS AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; ARIPIPRAZOLE; ATENOLOL; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BENAZEPRIL; BENZODIAZEPINE DERIVATIVE; BENZOPORPHYRIN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA1A INTERFERON; BEXAROTENE; BISPHOSPHONIC ACID DERIVATIVE; BLEPH 10; BREVOXYL; BRUMEX; CALCIPOTRIOL; CAPECITABINE; CAPTOPRIL; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CARVEDILOL; CELECOXIB; CETIRIZINE; CETUXIMAB; CEVIMELINE; CHLORHEXIDINE GLUCONATE; CHLOROQUINE; CHLOROTHIAZIDE; CHLORPHENIRAMINE MALEATE; CHLORPROMAZINE; CHLORPROPAMIDE; CHLORTALIDONE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CIDOFOVIR; CIPROFLOXACIN; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CROMOGLYCATE DISODIUM; CYCLOBENZAPRINE; CYCLOOXYGENASE 2 INHIBITOR; DACARBAZINE; DANTROLENE; DEMECLOCYCLINE; DESIPRAMINE; DIAMOX SEQUELS; DICLOFENAC; DILTIAZEM; DIMENHYDRINATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; DISOPYRAMIDE PHOSPHATE; DOCETAXEL; DOXEPIN; DOXYCYCLINE; DULOXETINE; EFAVIRENZ; ENALAPRIL MALEATE; EPIRUBICIN; ESTAZOLAM; ESZOPICLONE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHIONAMIDE; ETIDRONIC ACID; ETODOLAC; ETRETIN; FELBAMATE; FENOFIBRATE; FLUCYTOSINE; FLUINDOSTATIN; FLUOROURACIL; FLUOXETINE; FLUPHENAZINE; FLURBIPROFEN; FLUVOXAMINE MALEATE; FOSINOPRIL; FUROSEMIDE; GABAPENTIN; GANCICLOVIR; GANTRISIN PEDIATRIC; GEMIFLOXACIN; GLATIRAMER; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GRISEOFULVIN; HALOPERIDOL; HEXACHLOROPHENE; HEXACYCLINE; HYDROMORPHONE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; IMATINIB; IMIPRAMINE; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; INDAPAMIDE; INTERFERON BETA SERINE; IONIL T PLUS; ISOTRETINOIN; ITRACONAZOLE; J TAN; KERATOLYTIC AGENT; KETOPROFEN; LABETALOL; LAMOTRIGINE; LEUPRORELIN; LEVOFLOXACIN; LISINOPRIL; LOOP DIURETIC AGENT; LORATADINE; LOSARTAN POTASSIUM; MACROLIDE; MEFENAMIC ACID; MELOXICAM; MESALAZINE; METOLAZONE; MEVINOLIN; MINOCYCLINE; MIRTAZAPINE; MITOMYCIN C; MOEXIPRIL; NABUMETONE; NALIDIXIC ACID; NAPROXEN; NARATRIPTAN; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; NORTRIPTYLINE; OFLOXACIN; OLANZAPINE; OLSALAZINE; OMEPRAZOLE; OXAPROZIN; OXCARBAZEPINE; OXYCODONE; PALGIC; PAMIDRONIC ACID; PANTOPRAZOLE; PAROXETINE; PENTOSAN POLYSULFATE; PENTOSTATIN; PHENYTOIN; PHOTOFRIN; PILOCARPINE; PIROXICAM; POLYLACTIC ACID; PRAVASTATIN; PROCHLORPERAZINE MALEATE; PROMETHAZINE; PROPRANOLOL; PROTRIPTYLINE; QUETIAPINE; QUINAPRIL; RABEPRAZOLE; RAMIPRIL; RECOMBINANT ALPHA2B INTERFERON; RETINOIC ACID; RETINOID; RILUZOLE; RISEDRONIC ACID; RISPERIDONE; RITONAVIR; RIZATRIPTAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROPINIROLE; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SAQUINAVIR; SELEGILINE; SEROTONIN AGONIST; SERTRALINE; SOTALOL; SPARFLOXACIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; SULINDAC; SUMATRIPTAN SUCCINATE; TABLOID; TAVIST ALLERGY; TAZAROTENE; TERCONAZOLE; THALIDOMIDE; TIAGABINE; TIOTIXENE; TOPIRAMATE; TORASEMIDE; TRAZODONE; TREXALL; TRIAMCINOLONE ACETONIDE; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; TRIMIPRAMINE; TSUKUBAENOLIDE; UNINDEXED DRUG; UROLENE BLUE; UVADEX; VALACICLOVIR; VALPROIC ACID; VALSARTAN; VARDENAFIL; VENLAFAXINE; VORICONAZOLE; WARFARIN; ZALCITABINE; ZALEPLON; ZIPRASIDONE; ZOLMITRIPTAN; ZOLPIDEM TARTRATE;

BLISTER; CLINICAL PHARMACY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; PHOTOALLERGY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PRURITUS; RASH; REVIEW;

EID: 33644527285     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4102-196     Document Type: Review

References (96)

1. Facts & Comparisons 4.0 [database online]. St. Louis, MO: Wolters Kluwer Health.
2. Frishman WH, Brosnan BD, Grossman M; Dasgupta D, Sun AD. Adverse dermatologic effects of cardiovascular drug therapy: part I. Cardiol Rev. 2002;10(4):230-246.
3. th ed. McGraw-Hill, Ballantine, NY; 2002;1708.
4. Cardizem LA [package insert]. Biovail Pharmaceuticals; 2004.
5. Taylor CR. Photosensitivity: classification, diagnosis, and treatment. Dermatol Nurs. 1998;10(5):323-330.
6. Racette AJ, Roenigk HH, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol. 2005;52(5 suppl):S81-S85.
7. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol Rev. 2002;10(5):285-300.
8. J-Tan [package insert]. Jaymac Pharmaceuticals; 2005.
9. Engin B, Oguz O. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses. Int J Dermatol. 2005;44(4):337-339.
10. Chlorpheniramine [package insert]. Time-Cap Labs; 1998.
11. Tolland J, Elborn S, McKenna K. Ciprofloxacin-induced phototoxicity in patients with cystic fibrosis. J Am Acad Dermatol. 2005;52(3)(suppl):158.
12. Clemastine [package insert]. Geneva Pharmaceuticals; 2001.
13. Treudler R, Georgieva J, Geilen CC, Orfanos CE. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol. 2004;50(5):783-785.
14. Dexchlorpheniramine [package insert]. Morton Grove Pharmaceuticals; 2002.
15. Shah N, Warnakulasuriya S. Amiodarone-induced peri-oral photosensitivity. J Oral Pathol Med. 2004;33(1):56-58.
16. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769-2802.
17. Ricciardi L, Fedele R, Mazzeo L, Saitta S, Mancuso V, Isola S. Adverse reactions to Pantoprazole. Scand J Gastroenterol. 2003;38(7):800.
18. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf. 2003;26(2):109-120.
19. Dawe RS, Ibbotson SH, Sanderson JB, Thompson EM, Ferguson J. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol. 2003;149(6):1232-1241.
20. Spironolactone: first report of photosensitivity: case report. Reactions Weekly. 2003;937:14.
21. Hautmann G, Lotti T. Psychoactive drugs and skin. J Eur Acad Dermatol Venereol. 2003;17(4):383-393.
22. Lim DS, Murphy GM. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol. 2003;149(1):213-214.
23. Morison WL. Solar urticaria due to progesterone compounds in oral contraceptives. Photodermatol Photoimmunol Photomed. 2003;19(3):155-156.
24. Cyproheptadine [package insert]. Pliva, Inc.; 2003.
25. Lozol [package insert]. Aventis Pharmaceuticals; 2002.
26. Flutamide [package insert]. Ivax Pharmaceuticals; 2002.
27. Lim DS, Triscott J. O'Brien's actinic granuloma in association with prolonged doxycycline phototoxicity. Australas J Dermatol. 2003;44(1):67-70.
28. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25(5):345-372.
29. Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol. 2002;3(4):239-246.
30. Azulfidine [package insert]. Pharmacia; 2002
31. Selvaag E, Petersen AB, Gniadecki R, Thorn T, Wulf HC. Phototoxicity to diuretics and antidiabetics in the cultured keratinocyte cell line HaCaT: evaluation by clonogenic assay and single cell gel electrophoresis (Comet Assay). Photodermatol Photoimmunol Photomed. 2002;18(2):90-95.
32. Correia O, Lomba VH, Azevedo R, Delgado L, Polonia J. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. Clin Exp Dermatol. 2001;26(5):455-456.
33. Bagheri H, Lhiaubet V, Montastruc JL, Chouini-Lalanne N. Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf. 2000;22(5):339-349.
34. George M. Methylene-blue-induced hyperbilirubinemia and phototoxicity in a neonate. Clin Pediatr. 2000;39(11):659.
35. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. Pediatrics. 1996;97(5):717-721.
36. Moyer DB. Continued treatment with fluorouracil for colon cancer despite severe phototoxic dermatitis. J Allerg Clin Immunol. 1996;97(1, part 3):341.
37. McKenna KE, Stern RS. Photosensitivity associated with combined UV-B and calcipotriene therapy. Arch Dermatol. 1995;131(11):1305-1307.
38. Yoshimoto E, Konishi M, Takahashi K, et al. The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. Intern Med. 2004;43:630-631.
39. Cordarone [package Insert]. Wyeth Pharmaceuticals; 2004.
40. Lipitor [package insert]. Pfizer; 2004.
41. Lescol [package insert]. Novartis; 2003.
42. Mevacor [package insert]. Merck &Co. Inc; 2005.
43. Pravachol [package insert]. Bristol-Myers Squibb; 2004.
44. Zocor [package insert]. Merck & Co. Inc; 2004.
45. Crestor [package insert]. AstraZeneca; 2005.
46. Sculptra [package insert]. Dermik Labs; 2004.
47. Coreg [package insert]. GlaxoSmithKline; 2005.
48. Lamictal [package insert]. GlaxoSmithKline; 2004.
49. Topamax [package insert]. Ortho-McNeil Pharmaceutical Inc; 2000.
50. Cozaar [package insert]. Merck & Co. Inc; 2004.
51. Effexor [package insert]. Wyeth Pharmaceuticals; 2005.
52. Gleevec [package insert]. Novartis; 2005.
53. Photofrin [package insert]. Axcan Scandipharm Inc; 2003.
54. Pentasa [package insert]. Shire US Inc; 2004.
55. Factive [package insert]. Oscient Pharmaceuticals; August 2004.
56. Zithromax [package insert]. Pfizer Labs; 2004.
57. Vistide [package insert]. Gilead Sciences, Inc; 2000.
58. Pyrazinamide [package insert]. Stada Pharmaceuticals, Inc; 2004.
59. Quinidine Gluconate Inj [package insert]. Eli Lilly Co; 1999.
60. Hydroxychloroquine Sulfate [package insert]. Mylan Pharmaceuticals, Inc; 2004.
61. Felbatol [package insert]. Med-Pointe Pharmaceuticals; 2003.
62. Doxycylcine Hyclate [package insert]. Mutual Pharmaceutical Co., Inc; 2004.
63. Dacarbazine [package insert]. Faulding Pharmaceutical Co; 2002.
64. Trecator [package insert]. Wyeth Pharmaceuticals; 2005.
65. Diabinese [package insert]. Pfizer Labs; 2001.
66. Cooper SM, George S. Photosensitivity reaction associated with use of the combined oral contraceptive. Br J Dermatol. 2001;144(3):641-642.
67. Zyrtec [package insert]. Pfizer Labs; 2004.
68. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25-61.
69. Martin-Garcia RF, del R Camacho N, Sanchez JL. Chloroquine-induced, vitiligo-like depigmentation. J Am Acad Dermatol. 2003;48(6 part 1):981-983.
70. Viagra [package insert]. Pfizer Labs; 2005.
71. Sporanox [package insert]. Abbott Laboratories, Inc; 2004.
72. Terazol [package insert]. Ortho-McNeil Pharmaceutical Inc; 2001.
73. Cutaneous drug reaction case reports: from the world literature. Am J Clin Dermatol. 2003;4(11):803-807.
74. Minocycline HCl [package insert]. Par Pharmaceuticals, Inc; 2004.
75. Trimethoprim [package insert]. Teva Pharmaceuticals, Inc; 2003.
76. ProSom [package insert]. Abbott Laboratories, Inc; 2004.
77. Mefenamic Acid [package insert]. First Horizon Pharmaceuticals Corporation; 2003.
78. Phenergan [package insert]. Wyeth Pharmaceuticals, Inc; 2004.
79. Norpramin [package insert]. Aventis Pharmaceuticals, Inc; 2005.
80. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321(5):327-335.
81. Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy. 1998;18(4):866-868.
82. Frishman WH, Brosnan BD, Grossman M, Dasgupta, D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10(6):337-348.
83. Diphenhydramine [package insert]. American Pharmaceutical Partner, Inc; 2002.
84. Palgic [package insert]. Pamlab, LLC.; 2002.
85. Phenergan [package insert]. Wyeth Pharmaceuticals; 2004.
86. Sular [package insert]. First Horizon Pharmaceutical; 2004.
87. Betapace [package insert]. Berlex Laboratories; 2003.
88. Cytovene [package insert]. Roche; 2003.
89. Eich D; Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Kreig T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25(6):599-602.
90. Danazol [package insert]. Barr Laboratories; 1999.
91. Tolazamide [package insert]. Mylan Pharmaceuticals; 2001.
92. Requip [package insert]. Glaxo SmithKline; 2005.
93. Gabitril [package insert]. Cephalon, Inc; 2001.
94. Gentamicin [package insert]. Taro Pharmaceuticals; 2004.
95. Flexeril [package insert]. McNeil Consumer; 2005.
96. Surmontil [package insert]. Odyssey Pharmaceuticals; 2001.